menu
    • menu
    [{"orgOrder":0,"company":"CombiGene","sponsor":"Cobra Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"CG01","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"CombiGene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"CombiGene \/ Cobra Biologics","highestDevelopmentStatusID":"4","companyTruncated":"CombiGene \/ Cobra Biologics"},{"orgOrder":0,"company":"CombiGene","sponsor":"Spark Therapeutics, Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"CG01","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"CombiGene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"CombiGene \/ CombiGene AB","highestDevelopmentStatusID":"4","companyTruncated":"CombiGene \/ CombiGene AB"}]

    Find Clinical Drug Pipeline Developments & Deals by CombiGene

    Menu

    CombiGene

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CombiGene

                            Sweden arrow
                            American Pharma Summit
                            Not Confirmed

                            CombiGene

                            Sweden arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CG01

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : Spark Therapeutics, Inc

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Spark Therapeutics and CombiGene Enter into Exclusive, Global Licensing Agreement for Gene Therapy Candidate C...

                            Details : The agreement provides Spark with the exclusive, worldwide license to develop, manufacture and commercialize CG01. CombiGene will continue to execute certain aspects of the preclinical program in collaboration with Spark.

                            Brand Name : CG01

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 12, 2021

                            Lead Product(s) : CG01

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : Spark Therapeutics, Inc

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CombiGene

                            Sweden arrow
                            American Pharma Summit
                            Not Confirmed

                            CombiGene

                            Sweden arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CG01

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Cobra Biologics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cobra Biologics Completes Production of Master Cell Banks for CombiGene’s Epilepsy Gene Therapy Drug Candida...

                            Details : Cobra has successfully produced master cell banks for the three plasmids used as starting material for CombiGene’s gene therapy CG01.

                            Brand Name : CG01

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            August 18, 2020

                            Lead Product(s) : CG01

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Cobra Biologics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth